CN114901663A - 一类芳香杂环类化合物及其在药物中的应用 - Google Patents

一类芳香杂环类化合物及其在药物中的应用 Download PDF

Info

Publication number
CN114901663A
CN114901663A CN202180005943.1A CN202180005943A CN114901663A CN 114901663 A CN114901663 A CN 114901663A CN 202180005943 A CN202180005943 A CN 202180005943A CN 114901663 A CN114901663 A CN 114901663A
Authority
CN
China
Prior art keywords
hydrogen
deuterium
deuterated
pharmaceutically acceptable
nitrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180005943.1A
Other languages
English (en)
Inventor
杜锋田
王海波
张强
张涛
郭娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Zheye Biotechnology LLC
Original Assignee
Shanghai Zheye Biotechnology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Zheye Biotechnology LLC filed Critical Shanghai Zheye Biotechnology LLC
Publication of CN114901663A publication Critical patent/CN114901663A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

本发明提供一种芳香杂环类化合物蛋白抑制剂，其立体异构体、互变异构体或药学上可接受的盐，还提供了与该类化合物的制备和用途有关方法，包含这种化合物的药物组合物及相关治疗癌症的方法。本发明公开的含芳香杂环类化合物对蛋白具有选择性的显著抑制活性，在肿瘤治疗领域具有广泛应用前景。

Description

PCT国内申请，说明书已公开。

Claims (39)

  1. PCT国内申请，权利要求书已公开。
CN202180005943.1A 2020-03-02 2021-03-01 一类芳香杂环类化合物及其在药物中的应用 Pending CN114901663A (zh)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
CN202010136466 2020-03-02
CN202010136466X 2020-03-02
CN202010153287 2020-03-06
CN2020101532877 2020-03-06
CN202010163176 2020-03-10
CN2020101631764 2020-03-10
CN202010204480 2020-03-21
CN2020102044809 2020-03-21
CN2020102602716 2020-04-03
CN202010260271 2020-04-03
CN202011080704 2020-10-11
CN2020110807046 2020-10-11
CN202011114331 2020-10-19
CN202011114331X 2020-10-19
CN202011418425 2020-12-06
CN2020114184256 2020-12-06
PCT/CN2021/078555 WO2021175199A1 (zh) 2020-03-02 2021-03-01 一类芳香杂环类化合物及其在药物中的应用

Publications (1)

Publication Number Publication Date
CN114901663A true CN114901663A (zh) 2022-08-12

Family

ID=77614402

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180005943.1A Pending CN114901663A (zh) 2020-03-02 2021-03-01 一类芳香杂环类化合物及其在药物中的应用

Country Status (2)

Country Link
CN (1) CN114901663A (zh)
WO (1) WO2021175199A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
JP2022548791A (ja) 2019-09-24 2022-11-21 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
MX2022007515A (es) 2019-12-20 2022-09-19 Mirati Therapeutics Inc Inhibidores de sos1.
TW202227438A (zh) * 2020-11-24 2022-07-16 大陸商杭州多域生物技術有限公司 一種芳香化合物、其製備方法及應用
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
BR112023022819A2 (pt) 2021-05-05 2024-01-16 Revolution Medicines Inc Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula
CN117616031A (zh) 2021-05-05 2024-02-27 锐新医药公司 用于治疗癌症的ras抑制剂
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018217651A1 (en) * 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019051291A1 (en) * 2017-09-08 2019-03-14 Amgen Inc. KRAS G12C INHIBITORS AND METHODS OF USE
CN110366550A (zh) * 2016-12-22 2019-10-22 美国安进公司 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
US20190343838A1 (en) * 2018-05-04 2019-11-14 Amgen Inc. Kras g12c inhibitors and methods of using the same
US20190374542A1 (en) * 2018-06-12 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020233592A1 (en) * 2019-05-21 2020-11-26 Inventisbio Shanghai Ltd. Heterocyclic compounds, preparation methods and uses thereof
WO2020239077A1 (zh) * 2019-05-29 2020-12-03 上海翰森生物医药科技有限公司 含氮杂环类衍生物调节剂、其制备方法和应用
CN112159405A (zh) * 2020-02-04 2021-01-01 广州必贝特医药技术有限公司 吡啶并嘧啶酮类化合物及其应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110366550A (zh) * 2016-12-22 2019-10-22 美国安进公司 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
WO2018217651A1 (en) * 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019051291A1 (en) * 2017-09-08 2019-03-14 Amgen Inc. KRAS G12C INHIBITORS AND METHODS OF USE
US20190343838A1 (en) * 2018-05-04 2019-11-14 Amgen Inc. Kras g12c inhibitors and methods of using the same
US20190374542A1 (en) * 2018-06-12 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020233592A1 (en) * 2019-05-21 2020-11-26 Inventisbio Shanghai Ltd. Heterocyclic compounds, preparation methods and uses thereof
WO2020239077A1 (zh) * 2019-05-29 2020-12-03 上海翰森生物医药科技有限公司 含氮杂环类衍生物调节剂、其制备方法和应用
CN112159405A (zh) * 2020-02-04 2021-01-01 广州必贝特医药技术有限公司 吡啶并嘧啶酮类化合物及其应用

Also Published As

Publication number Publication date
WO2021175199A1 (zh) 2021-09-10

Similar Documents

Publication Publication Date Title
CN114901663A (zh) 一类芳香杂环类化合物及其在药物中的应用
US20230143751A1 (en) Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs
US10988484B2 (en) Glucose uptake inhibitors
CA2969090C (en) Triazolopyrimidine compounds and uses thereof
TWI714590B (zh) 吡啶並［３，４－ｄ］嘧啶衍生物及其藥學上可被許可的鹽
KR20220119088A (ko) Kras 돌연변이체 단백질 억제제
KR101692600B1 (ko) 증식성 질환 치료용 거대환형 유도체
JP6942380B2 (ja) 新規イソインドリン誘導体、その医薬組成物および使用
AU2019392231B2 (en) Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound
RU2537945C2 (ru) Триазиновые, пиримидиновые и пиридиновые аналоги и их применение в качестве терапевтических агентов и диагностических проб
US20230322732A1 (en) RIP1 Inhibitory Compounds and Methods for Making and Using the Same
WO2021143693A1 (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN103987707B (zh) 吡唑‑4‑基‑杂环基‑甲酰胺化合物以及使用方法
CN115052870B (zh) 一种芳香类化合物及其在抗肿瘤药物中的应用
JP6779899B2 (ja) Ｔｎｆ阻害剤として有用なヘテロ環式化合物
JP2022515335A (ja) 置換ピラゾロ［１，５－ａ］ピリジン化合物、該化合物を含む組成物およびその使用
CN112424185A (zh) 含苯环的化合物、其制备方法及应用
WO2021249563A1 (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN116249683A (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
WO2022037630A1 (zh) 四环类衍生物、其制备方法及其医药上的用途
JP7281834B2 (ja) Ｐｄ－ｌ１拮抗薬化合物
WO2021129841A1 (zh) 用作ret激酶抑制剂的化合物及其应用
TW202333667A (zh) 嘧啶或吡啶類衍生物及其醫藥用途
WO2024077057A1 (en) Phenyl oxy amide kinase inhibitors
CN117430597A (zh) 用作cdk4激酶抑制剂的化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination